[go: up one dir, main page]

Bhosale et al., 2024 - Google Patents

Development of tunable mechanism-based carbasugar ligands that stabilize glycoside hydrolases through the formation of transient covalent intermediates

Bhosale et al., 2024

View HTML
Document ID
12212330833448972695
Author
Bhosale S
Kandalkar S
Gilormini P
Akintola O
Rowland R
Adabala P
King D
Deen M
Chen X
Davies G
Vocadlo D
Bennet A
Publication year
Publication venue
ACS catalysis

External Links

Snippet

Mutations in many members of the set of human lysosomal glycoside hydrolases cause a wide range of lysosomal storage diseases. As a result, much effort has been directed toward identifying pharmacological chaperones of these lysosomal enzymes. The majority of the …
Continue reading at pubs.acs.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue

Similar Documents

Publication Publication Date Title
Tropak et al. Pharmacological enhancement of β-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients
Goddard-Borger et al. Rapid assembly of a library of lipophilic iminosugars via the thiol–ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease
Overkleeft et al. Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase
Guo et al. Selective inhibitors of human neuraminidase 1 (NEU1)
US10813921B2 (en) Method to predict response to pharmacological chaperone treatment of diseases
Gloster et al. Glycosidase inhibition: an assessment of the binding of 18 putative transition-state mimics
Siriwardena et al. Synthesis of 1, 5-Dideoxy-1, 5-iminoribitol C-Glycosides through a Nitrone–Olefin Cycloaddition Domino Strategy: Identification of Pharmacological Chaperones of Mutant Human Lysosomal β-Galactosidase
Lemieux et al. Crystallographic structure of human β-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis
Hertz et al. Gaucher disease provides a unique window into Parkinson disease pathogenesis
Williams et al. A new, simple, high-affinity glycosidase inhibitor: analysis of binding through X-ray crystallography, mutagenesis, and kinetic analysis
García-Moreno et al. Fluorinated Chaperone− β-Cyclodextrin Formulations for β-Glucocerebrosidase Activity Enhancement in Neuronopathic Gaucher Disease
Gonzalez-Cuesta et al. Bicyclic picomolar OGA inhibitors enable chemoproteomic mapping of its endogenous post-translational modifications
Fantur et al. Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB1 alleles causing GM1-gangliosidosis and Morquio B disease
Arenz Recent advances and novel treatments for sphingolipidoses
García-Moreno et al. Synthesis and evaluation of calystegine B2 analogues as glycosidase inhibitors
Ho et al. Development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-β-hexosaminidase inhibitors
González-Cuesta et al. sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease
Wilkinson et al. E scherichia coli Glucuronylsynthase: An Engineered Enzyme for the Synthesis of β-Glucuronides
de la Fuente et al. Stereoselective synthesis of 2-acetamido-1, 2-dideoxyallonojirimycin (DAJNAc), a new potent hexosaminidase inhibitor
Calvelo et al. Human O-GlcNAcase uses a preactivated boat-skew substrate conformation for catalysis. Evidence from X-ray crystallography and QM/MM metadynamics
Orwig et al. Binding of 3, 4, 5, 6-tetrahydroxyazepanes to the acid-β-glucosidase active site: Implications for pharmacological chaperone design for Gaucher disease
Bhosale et al. Development of tunable mechanism-based carbasugar ligands that stabilize glycoside hydrolases through the formation of transient covalent intermediates
Nieman et al. Family 39 α-l-Iduronidases and β-d-Xylosidases React through Similar Glycosyl− Enzyme Intermediates: Identification of the Human Iduronidase Nucleophile
Ofman et al. An orthogonally protected cyclitol for the construction of nigerose-and dextran-mimetic cyclophellitols
Tsukimoto et al. In cellulo crystallization of human neuraminidase 1 and biological roles of N-glycans